TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23
Artiva Biotherapeutics Analyst Ratings
Artiva Biotherapeutics, Inc.: Strong Buy Rating Supported by Robust Autoimmune Pipeline and Financial Stability
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy From TD Cowen
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating
Artiva Biotherapeutics Analyst Ratings
Wedbush Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $18
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy From Wedbush
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23
Buy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong Financials
A Quick Look at Today's Ratings for Artiva Biotherapeutics(ARTV.US), With a Forecast Between $18 to $23
A Quick Look at Today's Ratings for Artiva Biotherapeutics(ARTV.US), With a Forecast Between $18 to $23
Artiva Biotherapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), BioMarin Pharmaceutical (BMRN) and Maravai Lifesciences Holdings (MRVI)
No Data
No Data